HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Metastatic placental site trophoblastic tumor: long-term remission in a patient treated with EMA/CO chemotherapy.

AbstractOBJECTIVE:
We document a case of long-term remission in a patient with metastatic placental site trophoblastic tumor (PSTT) and attempt to determine the response rate of metastatic PSTT to EMA/CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, and vincristine) combination chemotherapy based on available reports.
METHODS:
Medical records, histological slides, and radiological films were reviewed for a patient with metastatic PSTT diagnosed in 1991. Using Medline and cross-references, pertinent articles were reviewed.
RESULTS:
A 31-year-old patient with PSTT metastatic to the lungs and vagina is presently alive, without evidence of recurrent cancer, more than 6 years after treatment with EMA/CO chemotherapy and surgery. The total response rate for seven patients with metastatic PSTT treated with EMA/CO chemotherapy was 71% with a complete response rate of 28%.
CONCLUSIONS:
Metastatic PSTT is potentially curable. EMA/CO chemotherapy appears superior to older multiagent regimens used in treating PSTT.
AuthorsE Swisher, C W Drescher
JournalGynecologic oncology (Gynecol Oncol) Vol. 68 Issue 1 Pg. 62-5 (Jan 1998) ISSN: 0090-8258 [Print] United States
PMID9454662 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 1998 Academic Press.
Chemical References
  • Dactinomycin
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Methotrexate
Topics
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cyclophosphamide (administration & dosage)
  • Dactinomycin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Lung Neoplasms (diagnostic imaging, secondary)
  • Methotrexate (administration & dosage)
  • Pregnancy
  • Radiography
  • Remission Induction
  • Trophoblastic Tumor, Placental Site (drug therapy, pathology)
  • Uterine Neoplasms (drug therapy, pathology)
  • Vaginal Neoplasms (secondary)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: